|
gptkbp:instanceOf
|
gptkb:antibiotic
fluoroquinolone
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01MA12
|
|
gptkbp:bioavailability
|
99% (oral)
|
|
gptkbp:brand
|
Iquix
Levaquin
Quixin
Tavanic
|
|
gptkbp:CASNumber
|
100986-85-4
|
|
gptkbp:chemicalFormula
|
C18H20FN3O4
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
hypersensitivity to quinolones
|
|
gptkbp:developedBy
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:eliminationHalfLife
|
6-8 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
levofloxacin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DNA gyrase
inhibits topoisomerase IV
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
361.37 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:proteinBinding
|
24-38%
|
|
gptkbp:PubChem_CID
|
149096
|
|
gptkbp:riskFactor
|
gptkb:hypoglycemia
peripheral neuropathy
CNS effects
tendinitis
phototoxicity
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
ophthalmic
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
QT prolongation
insomnia
tendon rupture
|
|
gptkbp:UNII
|
K72T3FS567
|
|
gptkbp:usedFor
|
gptkb:sinusitis
gptkb:prostatitis
gptkb:pneumonia
skin infections
urinary tract infections
bacterial infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Fluoroquinolones
|
|
gptkbp:bfsLayer
|
5
|